Diadema Partners »

Evolus shares owned by Diadema Partners

Quarter-by-quarter ownership of Evolus (EOLS) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Evolus

Tip: Access up to 7 years of quarterly data

All positions including Evolus held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evolus by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $790k 119k 6.65

More positions owned by Diadema Partners

Viking Therapeutics (VKTX)
Vertex Pharmaceuticals Incorporated (VRTX)
Bridgebio Pharma (BBIO)
Spdr Series Trust State Street Spd Put Option (XBI)
Praxis Precision Medicines I Com New Put Option (PRAX)
Johnson & Johnson (JNJ)
Avidity Biosciences Ord Call Option (RNA)
Capricor Therapeutics Com New (CAPR)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Jazz Pharmaceuticals Shs Usd Call Option (JAZZ)
Terns Pharmaceuticals (TERN)
Apogee Therapeutics Call Option (APGE)
Structure Therapeutics Sponsored Ads Call Option (GPCR)
Regeneron Pharmaceuticals (REGN)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Diadema Partners

Top funds holding Evolus

Nantahala Capital Management
BlackRock
Vanguard Group
Braidwell
Frazier Life Sciences Management
Millennium Management
Stonepine Capital Management
State Street Corporation
Geode Capital Management
D. E. Shaw & Co
Tang Capital Management
Rice Hall James & Associates
Soleus Capital Management
Schroder Investment Management Group
UBS Group

View all funds holding Evolus